共 50 条
MDS research criteria for prodromal Parkinson's disease
被引:955
|作者:
Berg, Daniela
[1
,2
]
Postuma, Ronald B.
[3
]
Adler, Charles H.
[4
]
Bloem, Bastiaan R.
[5
]
Chan, Piu
[6
]
Dubois, Bruno
[7
]
Gasser, Thomas
[1
,2
]
Goetz, Christopher G.
[8
]
Halliday, Glenda
[9
]
Joseph, Lawrence
[10
]
Lang, Anthony E.
[11
]
Liepelt-Scarfone, Inga
[1
,2
]
Litvan, Irene
[12
]
Marek, Kenneth
[13
]
Obeso, Jose
[14
]
Oertel, Wolfgang
[15
]
Olanow, C. Warren
[16
]
Poewe, Werner
[17
]
Stern, Matthew
[18
]
Deuschl, Guenther
[19
]
机构:
[1] Hertie Inst Clin Brain Res, Dept Neurodegenerat, Tubingen, Germany
[2] German Ctr Neurodegenerat Dis, Tubingen, Germany
[3] Montreal Gen Hosp, Dept Neurol, Montreal, PQ H3G 1A4, Canada
[4] Mayo Clin, Parkinsons Dis & Movement Disorders Ctr, Dept Neurol, Scottsdale, AZ USA
[5] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Neurol, NL-6525 ED Nijmegen, Netherlands
[6] Capitol Med Univ, Xuanwu Hosp, Beijing, Peoples R China
[7] Hop De La Salpetriere, Paris, France
[8] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[9] Neurosci Res Australia & Univ NSW, Randwick, NSW, Australia
[10] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada
[11] Toronto Western Hosp, Div Neurol, Toronto, ON M5T 2S8, Canada
[12] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA
[13] Inst Neurodegenerat Disorders, New Haven, CT USA
[14] Univ Navarra, FIMA, E-31080 Pamplona, Spain
[15] Univ Marburg, Dept Neurol, Marburg, Germany
[16] Mt Sinai Hosp, Dept Neurol, New York, NY 10029 USA
[17] Med Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria
[18] Penn Neurol Inst, Philadelphia, PA USA
[19] Univ Kiel, Dept Neurol, Kiel, Germany
关键词:
Parkinson's disease;
diagnosis;
prodromal;
SLEEP BEHAVIOR DISORDER;
MILD COGNITIVE IMPAIRMENT;
REM-SLEEP;
FAMILIAL AGGREGATION;
RISK-FACTORS;
NEURODEGENERATIVE DISEASE;
OLFACTORY DYSFUNCTION;
DELAYED EMERGENCE;
SUBSTANTIA-NIGRA;
SUBSEQUENT RISK;
D O I:
10.1002/mds.26431
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
This article describes research criteria and probability methodology for the diagnosis of prodromal PD. Prodromal disease refers to the stage wherein early symptoms or signs of PD neurodegeneration are present, but classic clinical diagnosis based on fully evolved motor parkinsonism is not yet possible. Given the lack of clear neuroprotective/disease-modifying therapy for prodromal PD, these criteria were developed for research purposes only. The criteria are based upon the likelihood of prodromal disease being present with probable prodromal PD defined as 80% certainty. Certainty estimates rely upon calculation of an individual's risk of having prodromal PD, using a Bayesian naive classifier. In this methodology, a previous probability of prodromal disease is delineated based upon age. Then, the probability of prodromal PD is calculated by adding diagnostic information, expressed as likelihood ratios. This diagnostic information combines estimates of background risk (from environmental risk factors and genetic findings) and results of diagnostic marker testing. In order to be included, diagnostic markers had to have prospective evidence documenting ability to predict clinical PD. They include motor and nonmotor clinical symptoms, clinical signs, and ancillary diagnostic tests. These criteria represent a first step in the formal delineation of early stages of PD and will require constant updating as more information becomes available. (c) 2015 International Parkinson and Movement Disorder Society
引用
收藏
页码:1600 / 1609
页数:10
相关论文